-
Mathematical modelling of clonal reduction therapeutic strategies in acute myeloid leukemia Leuk. Res. (IF 2.7) Pub Date : 2024-03-16 Mia Brunetti, Isabella A. Iasenza, Adrianne L. Jenner, Noël J-M Raynal, Kolja Eppert, Morgan Craig
Over the years, the overall survival of older patients diagnosed with acute myeloid leukemia (AML) has not significantly increased. Although standard cytotoxic therapies that rapidly eliminate dividing myeloblasts are used to induce remission, relapse can occur due to surviving therapy-resistant leukemic stem cells (LSCs). Hence, anti-LSC strategies have become a key target to cure AML. We have recently
-
Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: A multicenter real-world experience Leuk. Res. (IF 2.7) Pub Date : 2024-03-15 Ebru Kilic Gunes, Sureyya Yigit Kaya, Fatih Yaman, Mustafa Kemal Yeniay, Kurtulus Vural, Melda Comert, Omur Gokmen Sevindik, Neslihan Andic, Simten Dagdas, Ilknur Nizam Ozen, Leylagul Kaynar, Filiz Yavasoglu, Gulsum Ozet, Volkan Karakus, Meltem Ayli
Thrombocytopenia is among the most common complications following hematopoietic stem cell transplantation and is associated with increased mortality and morbidity with no standard treatment yet. In this multicenter and retrospective study, we aim to present our multi-center experience of Eltrombopag treatment in patients with isolated thrombocytopenia following HSCT. A total of 73 patients from 5 centers
-
Clinical validation of a 10-color flow cytometry panel to detect measurable residual disease in acute myeloid leukemia Leuk. Res. (IF 2.7) Pub Date : 2024-03-13 Maura R V Ikoma-Colturato, Alef Rafael Severino, Juliana Fernanda dos Santos Tosi, Camila Marques Bertolucci, Yeda Midori Nakamura Cuoco, Ederson Roberto de Mattos, Iago Colturato, Fernanda Barbieri Rodrigues Silva, Mair Pedro de Souza, Anderson João Simione, Vergilio Antonio Rensi Colturato
-
Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study Leuk. Res. (IF 2.7) Pub Date : 2024-03-12 Guillermo Garcia-Manero, Maciej Kazmierczak, Agnieszka Wierzbowska, Chun Yew Fong, Michael K. Keng, Gianluca Ballinari, Francesco Scarci, Lionel Adès
Non-intensive therapies such as the hypomethylating agent (HMA) azacitidine (AZA) have been used in patients with AML ineligible for intensive induction chemotherapy (IC) or stem cell transplant due to advanced age, comorbidities, and/or risk factors. However, response rates and survival remain dismal. Pre-clinical studies indicate the epigenetic combination of HMAs and HDAC inhibitors induce re-expression
-
Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study Leuk. Res. (IF 2.7) Pub Date : 2024-03-12 Chao-Ling Wan, Yuan-Hong Huang, Si-Man Huang, Yan-Li Xu, Kai-Wen Tan, Yan-Qiu, Xiang-Dong Shen, Shuai-Shuai Ge, Han-Yu Cao, Yan-Yan Li, Song-Bai Liu, Jia-Jun Qi, Hai-Ping Dai, Sheng-Li Xue
is one of the recurrent mutated genes in newly diagnosed acute myeloid leukemia (AML). Although historically recognized as a provisional distinct entity, the AML subtype with mutations (AML-) was eliminated from the 2022 WHO classification system. To gain more insight into the characteristics of AML-, we retrospectively analyzed 1065 newly diagnosed adult AML patients from the First Affiliated Hospital
-
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study Leuk. Res. (IF 2.7) Pub Date : 2024-03-11 B. Douglas Smith, Tim H. Brümmendorf, Gail J. Roboz, Carlo Gambacorti-Passerini, Aude Charbonnier, Andrea Viqueira, Eric Leip, Simon Purcell, Erinn Hoag Goldman, Francis Giles, Thomas Ernst, Andreas Hochhaus, Gianantonio Rosti
The BYOND study evaluated the efficacy and safety of bosutinib 500 mg once daily in patients with chronic myeloid leukemia (CML) resistant/intolerant to prior tyrosine kinase inhibitors (TKIs). These post-hoc analyses assessed the efficacy and safety of bosutinib by resistance or intolerance to prior TKIs (imatinib-resistant vs dasatinib/nilotinib-resistant vs TKI-intolerant), and cross-intolerance
-
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123 Leuk. Res. (IF 2.7) Pub Date : 2024-03-11 Xiaoyi Hu, Asiri Ediriwickrema, Atif Saleem, Brent Tan, Naveen Pemmaraju, Gabriel N. Mannis
-
Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines Leuk. Res. (IF 2.7) Pub Date : 2024-03-07 Mara N. Zeissig, Duncan R. Hewett, Krzysztof M. Mrozik, Vasilios Panagopoulos, Craig T. Wallington-Gates, Andrew Spencer, Sandra M. Dold, Monika Engelhardt, Kate Vandyke, Andrew C.W. Zannettino
The proteasome inhibitor bortezomib is one of the primary therapies used for the haematological malignancy multiple myeloma (MM). However, intrinsic or acquired resistance to bortezomib, via mechanisms that are not fully elucidated, is a barrier to successful treatment in many patients. Our previous studies have shown that elevated expression of the chemokine receptor CCR1 in MM plasma cells in newly
-
Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia Leuk. Res. (IF 2.7) Pub Date : 2024-02-28 Garrett Bourne, Kendall Diebold, Manuel Espinoza-Gutarra, Zaid Al-Kadhimi, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Ravi Bhatia, Omer Jamy
In a meta-analysis of 5 trials, the addition of gemtuzumab ozogamicin (GO) to intensive induction chemotherapy led to a survival benefit in patients with core-binding factor (CBF) acute myeloid leukemia (AML). Given the heterogeneous incorporation of GO in clinical trials, the ideal dose and schedule remains unclear. We conducted a single-center retrospective analysis to compare outcomes of patients
-
Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia Leuk. Res. (IF 2.7) Pub Date : 2024-02-27 Sharon Zhong, Heena Kurish, Robert Walchack, Hong Li, Jessi Edwards, Abhay Singh, Anjali Advani
Most patients with acute myeloid leukemia (AML) develop relapsed or refractory (R/R) disease after receiving initial induction chemotherapy. Salvage chemotherapy followed by allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only curative therapy for R/R AML. Mitoxantrone, etoposide, and cytarabine (MEC) is the current standard of care salvage regimen for R/R AML at Cleveland Clinic
-
Phytostilbenes in lymphoma: Focuses on the mechanistic and clinical prospects of resveratrol, pterostilbene, piceatannol, and pinosylvin Leuk. Res. (IF 2.7) Pub Date : 2024-02-24 Pouya Goleij, Pantea Majma Sanaye, Mehregan Babamohamadi, Mohammad Amin Khazeei Tabari, Roshanak Amirian, Aryan Rezaee, Hamed Mirzaei, Alan Prem Kumar, Gautam Sethi, Sarvin Sadreddini, Philippe Jeandet, Haroon Khan
Lymphoma is a cancer affecting the lymphatic system that fights infections and diseases. In addition to surgery, radiotherapy, and chemotherapy, novel approaches have recently been investigated, such as phytostilbenes in treating lymphoma. Phytostilbenes are natural compounds present in various plants and have been shown to have different therapeutic effects, including anticancer properties. Resveratrol
-
A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results? Leuk. Res. (IF 2.7) Pub Date : 2024-02-23 Yulia Sidi, Cassie Dong, Yujun Wu, Douglas V. Faller
Despite emerging novel therapies, treating acute myeloid leukemia (AML) remains challenging. Complexities persist in designing pivotal clinical trials and establishing acceptable endpoints for AML. Recent FDA guidance for drug and biological products development for AML outlines considerations for trial design. The guidance defines overall survival (OS) and event-free survival (EFS) as endpoints representing
-
KRAS mutations, autoimmunity and female sex in chronic myelomonocytic leukemia Leuk. Res. (IF 2.7) Pub Date : 2024-02-22 Afaf E.G. Osman, Anton Rets, Ami B. Patel
-
-
Clinical outcomes of patients with acute myeloid leukemia and cardiovascular disease Leuk. Res. (IF 2.7) Pub Date : 2024-02-20 Gabriela Sanchez-Petitto, Olga G. Goloubeva, Jack Masur, James Childress, Tahreem Iqbal, Max An, Safwan Muhammad, Justin Lawson, Grace Li, Brian Barr, Ashkan Emadi, Jennie Y. Law, Seung Tae Lee, Vu H. Duong, Maria R. Baer, Sandrine Niyongere
Incidence of both acute myeloid leukemia (AML) and cardiovascular disease (CVD) increases with age. We evaluated whether pre-existing CVD impacts clinical outcomes in AML. We retrospectively evaluated 291 consecutive adult AML patients treated at our institution, 2014–2020. Pretreatment comorbidities were identified by chart review. Outcomes included complete remission (CR) and CR with incomplete count
-
Adipose tissue indices predict prognosis in hodgkin lymphoma Leuk. Res. (IF 2.7) Pub Date : 2024-02-15 Demircan Özbalcı, Mehmet Erdoğan, Emine Güçhan Alanoğlu, Sevim Süreyya Şengül, Kamuran Yüceer, Hande Nur Eroğlu, Samet Yağcı
This study evaluated the impact of adipose tissue indices on prognosis of HL. Fifty-five patients with newly diagnosed Hodgkin Lymphoma were evaluated retrospectively for association with adipose tissue indices (total abdominal tissue volume, radiodensity, subcutaneous and visceral adipose tissue SUVmax value and prognostic factors for Hodgkin Lymphoma such as IPS-3, IPS-7, stage, sedimentation, progression
-
Proteomic analysis of adult T-cell leukemia/lymphoma: A biomarker identification strategy based on preparation and in-solution digestion methods of total proteins Leuk. Res. (IF 2.7) Pub Date : 2024-02-12 Haruka Sudo, Yasuhiro Tonoyama, Emi Ikebe, Hiroo Hasegawa, Hidekatsu Iha, Yo-ichi Ishida
Adult T-cell leukemia/lymphoma (ATL), caused by human T-cell leukemia virus type-1 (HTLV-1) infection, is a malignant hematologic cancer that remains difficult to cure. We herein established a biomarker identification strategy based on the total cell proteomics of cultured ATL cells to search for novel ATL biomarkers. Four protocols with a combination of selected conditions based on lysis buffers and
-
Bortezomib modulated the autophagy-lysosomal pathway in a TFEB-dependent manner in multiple myeloma Leuk. Res. (IF 2.7) Pub Date : 2024-02-12 Rongjuan Zhang, Xinhong Yang, Xiaomin Shi, Enhong Xing, Lihong Wang, Changlai Hao, Zhihua Zhang
To explore the involvement of TFEB-mediated autophagy-lysosomal mechanisms in multiple myeloma (MM) during bortezomib treatment. MM cells were exposed to bortezomib or subjected to TFEB knockdown. CCK assay was used to assess the cell proliferation. Western blotting and fluorescent staining were conducted to examine autophagy and lysosomes. The TFEB expression pattern was analyzed, and whole transcriptome
-
Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement Leuk. Res. (IF 2.7) Pub Date : 2024-02-06 Hannah Goulart, Dahniel Sastow, Erin Moshier, Lily Martin, John Mascarenhas, Douglas Tremblay
Patients with acute myeloid leukemia (AML) may experience extramedullary involvement when disease is present outside of the blood and bone marrow. In particular, the presence of central nervous system (CNS) involvement has traditionally been thought of as a poor prognostic factor. In the presently available literature, there is a paucity of conclusive data surrounding CNS AML given its rarity and lack
-
Clinical features and management of germline CEBPA-mutated carriers Leuk. Res. (IF 2.7) Pub Date : 2024-02-03 Lili Pan, Yining Li, Huiying Gao, Xiaolin Lai, Yuanhua Cai, Zhixiang Chen, Xiaofan Li, Shao-yuan Wang
-
Circ_0005615 enhances multiple myeloma progression through interaction with EIF4A3 to regulate MAP3K4 m6A modification mediated by ALKBH5 Leuk. Res. (IF 2.7) Pub Date : 2024-02-01 Kai Zhu, Feng quan Gou, Zi Wen Zhao, Ke Xu, Jian Song, Hongyi Jiang, Feng Zhang, Yan Li Yang, Jia jia Li
Circular RNAs (circRNAs) are associated with development and progression of multiple myeloma (MM). However, the role and mechanism of circ_0005615 in MM have not been elucidated. Circ_0005615 was determined by GEO database. quantitative RT-PCR was performed to confirm the expression of circ_0005615 in peripheral blood of MM patients and MM cells. The roles of circ_0005615 in MM were analyzed using
-
-
Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope Leuk. Res. (IF 2.7) Pub Date : 2024-01-23 M. Tarek Elghetany, Mrinal M. Patnaik, Joseph D. Khoury
Inherited bone marrow failure syndromes and germline predisposition syndromes (IBMFS/GPS) are associated with increased risk for hematologic malignancies, particularly myeloid neoplasms, such as myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The diagnosis of MDS in these syndromes poses difficulty due to frequent bone marrow hypocellularity and the presence of some degree of dysplastic
-
Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation Leuk. Res. (IF 2.7) Pub Date : 2024-01-23 Lara Boucher, Laura Rozalska, Nathalie Sorel, Gaëlle Olivier, Maria Pilar Gallego Hernanz, Emilie Cayssials, Anna Raimbault, Jean-Claude Chomel
Abstract not available
-
When the devil is in the details: Similarities and differences between WHO and ICC classifications of AML Leuk. Res. (IF 2.7) Pub Date : 2024-01-17 Sergio Ramos-Cillan, Daniel Láinez-González, Laura Solan, Carlos Blas, Rocío Salgado, Tamara Castaño, Javier Cornago, Pilar Llamas, Juan Manuel Alonso-Dominguez
Abstract not available
-
Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults Leuk. Res. (IF 2.7) Pub Date : 2024-01-17 Iekuni Oh, Kaoru Hatano, Takashi Ikeda, Yumiko Toda, Daisuke Minakata, Shinichiro Kawaguchi, Kaoru Morita, Chihiro Yamamoto, Masahiro Ashizawa, Kazuya Sato, Kazuaki Kameda, Ayumi Gomyo, Yukiko Misaki, Shunto Kawamura, Shunichi Kimura, Hiroyuki Kobayashi, Hiroyuki Sato, Hideki Nakasone, Ken Ohmine, Shinichiro Fujiwara, Yoshinobu Kanda
Abstract not available
-
Corrigendum to “Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia” [Leuk. Res. (2022) 106946] Leuk. Res. (IF 2.7) Pub Date : 2024-01-09 Andrew J. Klink, Ajeet Gajra, Russell L. Knoth, Landon Marshall, Ying Hou, Ali McBride, Ronda Copher
-
Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b Leuk. Res. (IF 2.7) Pub Date : 2024-01-09 Ben K. Seon, Morihiro Okazaki, Jill Duzen, Fumihiko Matsuno, Andrew K.L. Goey, Orla Maguire
We identified unique molecular heterogeneity of CD79 of human B cell antigen receptor (BCR) that may open a new approach to the ongoing CD79b-targeted therapy of B cell tumors. The primary purpose of the present study is to gain new information valuable for the enhanced CD79-targeted therapy. The molecular heterogeneity of CD79 was identified by sequential immunoprecipitation of BCR by use of anti-CD79b
-
Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study Leuk. Res. (IF 2.7) Pub Date : 2024-01-09 Ibrahim Didi, Jean-Marc Alliot, Pierre-Yves Dumas, François Vergez, Suzanne Tavitian, Laëtitia Largeaud, Audrey Bidet, Jean-Baptiste Rieu, Isabelle Luquet, Nicolas Lechevalier, Eric Delabesse, Audrey Sarry, Anne-Charlotte De Grande, Emilie Bérard, Arnaud Pigneux, Christian Récher, David Simoncini, Sarah Bertoli
-
Altered lipid metabolism in patients with acute graft-versus-host disease after allogeneic hematopoietic cell transplantation Leuk. Res. (IF 2.7) Pub Date : 2024-01-05 Martyna Tyszka, Dominika Maciejewska-Markiewicz, Daniel Styburski, Jarosław Biliński, Agnieszka Tomaszewska, Ewa Stachowska, Grzegorz W. Basak
Allogeneic hematopoietic cell transplantation (allo-HCT) remains the sole curative option for many hematological malignancies and other diseases. Nevertheless, its application is limited due to the risk of life-threatening complications, mainly graft-versus-host disease (GVHD). Currently, in clinical practice, the risk of developing GVHD is estimated for every patient based on factors related to the
-
Spectrum of therapy-related clonal cytopenias and neoplasms after exposure to Lutetium-177-Dotatate Leuk. Res. (IF 2.7) Pub Date : 2023-12-25 Stephanie L. Pritzl, Yael Kusne, Thorvardur R. Halfdanarson, Timothy Hobday, Mohamad Bassam Sonbol, Ayse Tuba Kendi, Abhishek A. Mangaonkar, Naseema Gangat, Mithun Shah, Mrinal M. Patnaik
Abstract not available
-
The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms Leuk. Res. (IF 2.7) Pub Date : 2023-12-19 Vishesh Khanna, Rong Lu, Jyoti Kumar, Alfonso Molina, Henning Stehr, Elizabeth Spiteri, Michael Spinner, Oscar Silva, Sebastian Fernandez-Pol, Brent Tan, Peter L. Greenberg
Myelodysplastic neoplasms (MDS) are clonal disorders of bone marrow failure exhibiting a variable risk of progression to acute myeloid leukemia. MDS exhibit certain prognostic genetic or cytogenetic abnormalities, an observation that has led to both the pathologic reclassification of MDS in the 2022 World Health Organization (WHO) and International Consensus Classification (ICC) systems, as well as
-
VEXAS syndrome in a patient with DDX41 germline predisposition syndrome Leuk. Res. (IF 2.7) Pub Date : 2023-12-15 Yael Kusne, Terra Lasho, Christy Finke, Mrinal M. Patnaik, Talha Badar
Abstract not available
-
Evaluation of palonosetron, fosaprepitant, and olanzapine as antiemetic prophylaxis for fludarabine and melphalan-based conditioning regimens prior to allogeneic hematopoietic stem cell transplants Leuk. Res. (IF 2.7) Pub Date : 2023-11-28 Riley Karpen, Jeremy Sen, Sarah Wall, Samantha Musson, Justin Tossey
Limited data are available regarding efficacious antiemetic regimens to prevent chemotherapy-induced nausea and vomiting (CINV) for patients undergoing allogeneic hematopoietic stem cell transplant (HSCT). In patients aged 60 years or older, allogeneic HSCT is associated with improved survival, but tolerability of the transplant is a significant barrier. Fludarabine and melphalan (Flu–Mel) is a frequently
-
-
Low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell transplant in patients with acute myeloid leukemia failing conventional intensive chemotherapy Leuk. Res. (IF 2.7) Pub Date : 2023-11-23 Michael Ashby, Shaun Fleming, Tse-Chieh Teh, Ing Soo Tiong, Shafqat Inam, David J. Curtis, Sushrut Patil, Catherine Vassili, Chong Chyn Chua
Abstract not available
-
Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience Leuk. Res. (IF 2.7) Pub Date : 2023-11-18 Irene Urbino, Carolina Secreto, Vincenzo Apolito, Matteo Olivi, Giulia Arrigo, Eleonora Boscaro, Federica Maria Catania, Stefano D’Ardia, Chiara Frairia, Valentina Giai, Roberto Freilone, Benedetto Bruno, Giuseppe Lanzarone, Luisa Giaccone, Alessandro Busca, Chiara Maria Dellacasa, Dario Ferrero, Ernesta Audisio, Marco Cerrano
Abstract not available
-
The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective Leuk. Res. (IF 2.7) Pub Date : 2023-11-10 Carlo Pescia, Gianluca Lopez, Daniele Cattaneo, Cristina Bucelli, Umberto Gianelli, Alessandra Iurlo
-negative myeloproliferative neoplasms (MPNs) are classically represented by polycythemia vera, essential thrombocythemia, and primary myelofibrosis. -negative MPNs are significantly associated with morbidity and mortality related to an increased risk of thrombo-hemorrhagic events. They show a consistent association with splanchnic vein thrombosis (SVT), either represented by the portal, mesenteric
-
Venetoclax-based therapy in treatment-naïve and relapsed/refractory acute myeloid leukemia Leuk. Res. (IF 2.7) Pub Date : 2023-10-31 Aditya Ravindra, Luna Acharya, Bradley Loeffler, Sarah Mott, Grerk Sutamtewagul, Prajwal Dhakal
Combining venetoclax with the hypomethylating agents azacitidine or decitabine has shown high complete response rates (60–70 %) in newly diagnosed (ND) acute myeloid leukemia (AML). However, studies addressing the efficacy of this approach in relapsed/refractory (R/R) AML remain limited. We conducted a retrospective analysis on patients treated with venetoclax-based therapy at a single institution
-
A comprehensive comparison between TBI vs non-TBI-based conditioning regimen in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis Leuk. Res. (IF 2.7) Pub Date : 2023-10-28 Faezeh Ansari, Maryam Behfar, Leila Jafari, Rashin Mohseni, Parisa Naji, Yalda Karamlou, Mohammad Hossein Amirzade-Iranaq, Amir Ali Hamidieh
Introduction We aimed to evaluate the efficacy, safety, and latent toxicity of total body irradiation (TBI)-based conditioning regimens compared to non-TBI regimens for pediatric patients (under 18 years old) with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Methods A systematic search was performed on MEDLINE, Scopus, WOS, and PMC. Also,
-
How low can you go?: Methodologic considerations in clonal hematopoiesis variant calling Leuk. Res. (IF 2.7) Pub Date : 2023-11-02 J. Scott Beeler, Kelly L. Bolton
Clonal hematopoiesis (CH) is defined by the presence of an expanded clonal hematopoietic cell population due to an acquired mutation conferring a selective growth advantage and is known to predispose to hematologic malignancy. In this review, we discuss sequencing methods for CH detection in bulk sequencing data and corresponding bioinformatic approaches for variant calling, filtering, and curation
-
PRMT5 inhibitors for lower-risk myelodysplasia: Is there anywhere to move? Leuk. Res. (IF 2.7) Pub Date : 2023-10-26 Andrej Terzic, David J. Curtis
Abstract not available
-
A new sequential conditioning regimen based on CPX- 351/Vyxeos (“Vyx-Seq”) in patients with higher risk myelodysplastic syndromes Leuk. Res. (IF 2.7) Pub Date : 2023-10-16 A.B. Notarantonio, G. Roth-Guépin, C. Bonmati, M. Divoux, C. Kicki, S. Pagliuca, A. Campidelli, M.T. Rubio, M. D’Aveni-Piney
Abstract not available
-
Advances in diagnosis, treatment and prognostic factors of gastrointestinal DLBCL Leuk. Res. (IF 2.7) Pub Date : 2023-10-18 Qinqiao Lai, Yan Zhao, Haiqing Yan, Hongling Peng
Gastrointestinal diffuse large B-cell lymphoma (GI-DLBCL) is an extremely aggressive form of B-cell non-Hodgkin lymphoma (BNHL) which has complex histological characteristics and manifests a high degree of heterogeneity in terms of clinical, morphological, immunological, and genetic features. GI-DLBCL mainly spreads by infiltrating neighboring lymph nodes, and common gastrointestinal complications
-
A new prognostic risk model for acute myeloid leukemia patients based on telomere-related genes Leuk. Res. (IF 2.7) Pub Date : 2023-10-14 Fan Zhang, Hongmin Du, Chenxi Hu, Yongping Song
Telomere maintenance is critical to ensure unlimited cancer cell proliferation, but the role of telomere-related genes in acute myeloid leukemia (AML) has not yet been thoroughly discussed. This study aims to develop a new prognostic risk model based on telomere-related genes and analyze potential mechanisms and targets. Cox regression analyses were used to build the prognostic risk model. Kaplan-Meier
-
Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF Leuk. Res. (IF 2.7) Pub Date : 2023-09-30 Carlos Jiménez-Vicente, Alexandra Martínez-Roca, Helena Pomares, Sandra Castaño-Diez, Francesca Guijarro, Mònica López-Guerra, Alex Bataller, Daniel Esteban, Albert Cortés-Bullich, Amanda Isabel Pérez-Valencia, Ares Guardia-Torrelles, Inés Zugasti, Montserrat Rovira, Francesc Fernández-Avilés, Dolors Colomer, Montserrat Arnan, Marina Díaz-Beyá, Jordi Esteve
Abstract not available
-
Impact of active surveillance at time of diagnosis on overall survival in nodular lymphocyte-predominant Hodgkin lymphoma: A National Cancer Database study Leuk. Res. (IF 2.7) Pub Date : 2023-09-26 Victoria M. Rogness, Wei Wei, Matthew Cortese, Brian T. Hill
Abstract not available
-
The chaperone protein GRP78 released from MPN cells increases the expression of lysyl oxidase in a human stromal cell line Leuk. Res. (IF 2.7) Pub Date : 2023-09-23 Kei Nakajima, Megumi Suzuki, Ichiro Kawashima, Megumi Koshiisi, Takuma Kumagai, Takeo Yamamoto, Masaru Tanaka, Keita Kirito
Impaired function of the endoplasmic stress (ER) response causes numerous pathological conditions, including tissue fibrosis. In the present study, we aimed to determine the pathological role of ER stress response systems in myeloproliferative neoplasms (MPNs). We found increased expression of the chaperone protein glucose-regulated protein (GRP) 78, a central regulator of ER stress, in megakaryocytes
-
Deep immunophenotypic analysis of the bone marrow progenitor cells in myelodysplastic syndromes Leuk. Res. (IF 2.7) Pub Date : 2023-09-23 Afshin Shameli, Poonam Dharmani-Khan, Iwona Auer, Meer-Taher Shabani-Rad
Background Diagnosis of myelodysplastic syndromes (MDS) is often challenging and requires integration of clinical, morphologic, cytogenetics and molecular information. Flow cytometry immunophenotyping (FCIP) can support the diagnosis by demonstration of numerical and immunophenotypic abnormalities of progenitor and maturing myelomonocytic and erythroid populations. We have previously shown that comprehensive
-
Integrating electronic geriatric assessment and frailty screening for adults with acute myeloid leukemia to drive personalized treatment decisions Leuk. Res. (IF 2.7) Pub Date : 2023-09-23 Omer Hassan Jamy, Margaret Kasner, Sarah Wall, Stacey Ingram, D.'Ambra Dent, William N. Dudley, Leah Dudley, Julie M. Scott, Debra Wujcik
Purpose Evidenced based guidelines for patients with Acute Myeloid Leukemia (AML) acknowledge increasing importance of frailty assessment when deciding on treatment, yet comprehensive geriatric assessment (GA) results are not easily incorporated into clinic workflows and the electronic health record. This study assessed the feasibility of electronic GA use in a real-world environment. Methods Patients
-
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes Leuk. Res. (IF 2.7) Pub Date : 2023-09-20 Tamanna Haque, Felix López Cadenas, Blanca Xicoy, Ana Alfonso-Pierola, Uwe Platzbecker, Irit Avivi, Andrew M. Brunner, Jöerg Chromik, Daniel Morillo, Manish R. Patel, Jose Falantes, Heather A. Leitch, Ulrich Germing, Meir Preis, Laurie Lenox, Josh Lauring, Regina J. Brown, Anna Kalota, Jaydeep Mehta, Friederike Pastore, David Valcárcel
Splicing factor (SF) gene mutations are frequent in myelodysplastic syndromes (MDS), and agents that modulate RNA splicing are hypothesized to provide clinical benefit. JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, was evaluated in patients with lower-risk (LR) MDS in a multi-part, Phase 1, multicenter study. The objectives were to determine a tolerable dose and to characterize
-
TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemia Leuk. Res. (IF 2.7) Pub Date : 2023-09-20 Mark Gurney, Patricia T. Greipp, Troy Gliem, Ryan Knudson, Aref Al-Kali, Naseema Gangat, Terra Lasho, Abhishek A. Mangaonkar, Christy M. Finke, Mrinal M. Patnaik
Abstract not available
-
Factors associated with thrombo-hemorrhagic deaths in patients with Acute Promyelocytic leukemia treated with Arsenic Trioxide and all-trans retinoic acid Leuk. Res. (IF 2.7) Pub Date : 2023-09-19 Charanpreet Singh, Parathan Karunakaran, Uday Yanamandra, Nishant Jindal, Saloni Rani Kumar, Neha Saini, Aditya Jandial, Arihant Jain, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Narender Kumar, Shano Naseem, Jasmina Ahluwalia, Neelam Varma, Subhash Varma, Pankaj Malhotra
Acute Promyelocytic Leukemia (APL) is associated with excellent long-term outcomes. However, early mortality due to coagulopathy remains a challenge. In this study we examined the bleeding and thrombotic manifestations, as well as incidence of Early Death secondary to thrombosis/hemorrhage (ED-TH) in patients with APL. Early death (ED) was defined as death occurring within 30 days of induction therapy
-
Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations Leuk. Res. (IF 2.7) Pub Date : 2023-09-14 Shyam A. Patel, Elisa Bello, Andrew Wilks, Jonathan M. Gerber, Narayanan Sadagopan, Jan Cerny
Numerous recent advances have been made in therapeutic approaches toward acute myeloid leukemia (AML). Since 2017, we have seen eleven novel Food & Drug Administration (FDA)-approved medications for AML, all of which extend beyond the classical cytarabine-based cytostatic chemotherapy. In the recent two decades, the role of immune surveillance in AML has been intensively investigated. The power of
-
MDS-Comorbidity Index using register data has prognostic impact in Swedish MDS patients Leuk. Res. (IF 2.7) Pub Date : 2023-09-07 Gunnar Larfors, Daniel Moreno Berggren, Hege Garelius, Lars Nilsson, Bengt Rasmussen, Eva Hellström-Lindberg, Elisabeth Ejerblad
Comorbidities influence the mortality in patients with myelodysplastic syndromes, and a growing body of evidence suggest that comorbidity history should be used in addition to established prognostic indices. A comorbidity index specific for MDS, the MDS-CI, was introduced a decade ago. In this study we aim to construct an MDS-CI version based on diagnoses from register data only, to expand its use
-
Single centre retrospective analysis of extracorporeal photopheresis (ECP) therapy in patients heavily pre-treated for chronic graft-versus-host disease (cGvHD) with steroid failure Leuk. Res. (IF 2.7) Pub Date : 2023-09-09 Swe Mar Linn, Igor Novitzky-Basso, Christopher Patriquin, Ivan Pasic, Wilson Lam, Arjun Law, Fotios V. Michelis, Armin Gerbitz, Auro Viswabandya, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, David Barth, Dennis Dong Hwan Kim
Background Extracorporeal photopheresis (ECP) is recommended as a second- or later-line therapy for chronic GvHD (cGvHD). Benefits include reasonable response with avoidance of intense systemic immunosuppression, which can translate into lowering the risk of systemic toxicity and opportunistic infection. Methods We evaluated 75 patients treated with ECP for cGvHD from 2007 to 2021 at Princess Margaret
-
Corrigendum to “Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities” [Leuk. Res. 130 (2023) 1–7] Leuk. Res. (IF 2.7) Pub Date : 2023-09-04 Ismail Elbaz Younes, Lee Syler, Amira Hamed
Abstract not available
-
The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma Leuk. Res. (IF 2.7) Pub Date : 2023-09-01 Sumukh Arun Kumar, Jenny Gao, Shyam A. Patel
Mantle cell lymphoma (MCL) is a heterogeneous subtype of non-Hodgkin lymphoma that has been historically associated with poor 5-year overall survival rates, especially for aggressive variants. Traditional cytotoxic chemotherapy had been a mainstay of therapy for relapsed/refractory (R/R) MCL for many years until the advent of molecularly targeted therapies and cell-based approaches. However, a significant
-
AML with CEBPA mutations: a comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts Leuk. Res. (IF 2.7) Pub Date : 2023-08-29 Davidson Zhao, Qianghua Zhou, Mojgan Zarif, Entsar Eladl, Cuihong Wei, Eshetu G. Atenafu, Andre Schuh, Anne Tierens, Yu Wing Tony Yeung, Mark D. Minden, Hong Chang
-
PI3K/AKT inhibitor BEZ-235 targets CCND2 and induces G1 arrest in breast implant-associated anaplastic large cell lymphoma Leuk. Res. (IF 2.7) Pub Date : 2023-08-27 Stefan Nagel, Anja Fischer, Susanne Bens, Vivien Hauer, Claudia Pommerenke, Cord C. Uphoff, Margarete Zaborski, Reiner Siebert, Hilmar Quentmeier
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a mature, CD30-positive T-cell lymphoma lacking expression of the anaplastic lymphoma kinase (ALK). In contrast to ALK-positive ALCL, BIA-ALCL cells express cyclin D2 (CCND2) which controls cyclin dependent kinases 4 and 6 (CDK4/6). DNA methylation and expression analyses performed with cell lines and primary cells suggest that